RESUMO
In this study, the effect of melatonin on sodium arsenite (arsenite)-induced peripheral neurotoxicity was investigated using dorsal root ganglion (DRG) explants. After 24-hr incubation, arsenite (30 microm) consistently elevated the expression of heat shock protein 70 and haeme oxygenase-1, two well-known stress proteins, in the treated DRG explants. Co-incubation with melatonin (4 and 20 mm) concentration-dependently attenuated arsenite-induced elevation in stress proteins. Furthermore, melatonin inhibited arsenite-induced phosphorylation of p38 and DNA fragmentation. Inhibition by melatonin of arsenite-induced apoptosis was mediated via inactivating both endoplasmic reticulum (ER) and mitochondrial pathways. In the ER pathway, melatonin suppressed arsenite-induced elevation in activating transcription factor-6 and CCAAT/enhancer-binding protein homologous protein in the nuclear fraction of the treated DRG explants. Moreover, melatonin attenuated arsenite-induced activation of caspase 12, an ER-specific enzyme. In the mitochondrial pathway, arsenite-induced increases in Bcl-2 levels and cytosolic cytochrome c were reduced by melatonin. At the same time, melatonin inhibited arsenite-induced activation of caspase 3 in the treated DRG explants. Compared with glutathione and N-acetyl cysteine, melatonin was more potent than either in inhibiting arsenite-induced elevation in stress proteins. Taken together, our study demonstrates that melatonin is protective against arsenite-induced neurotoxicity in DRG explants. In addition, melatonin prevented arsenite-induced apoptosis via suppression of ER and mitochondrial activation. Our data suggest that melatonin is potentially a therapy for arsenite-induced peripheral neuropathy.
Assuntos
Arsenitos/antagonistas & inibidores , Arsenitos/toxicidade , Melatonina/farmacologia , Fármacos Neuroprotetores/farmacologia , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/prevenção & controle , Análise de Variância , Animais , Gânglios Espinais/efeitos dos fármacos , Gânglios Espinais/metabolismo , Proteínas de Choque Térmico HSP70/metabolismo , Proteínas de Choque Térmico/metabolismo , Heme Oxigenase-1/metabolismo , Masculino , Melatonina/metabolismo , Fármacos Neuroprotetores/metabolismo , Síndromes Neurotóxicas/metabolismo , Doenças do Sistema Nervoso Periférico/metabolismo , Ratos , Ratos Sprague-DawleyRESUMO
Chronic exposure to arsenic causes health problems, including peripheral neuropathy. Oxidative stress is one of the mechanisms underlying arsenic-induced neurotoxicity. For this report, we studied the protective effect of N-acetylcysteine (NAC) on arsenic-induced oxidative injury in dorsal root ganglion (DRG) explants. After 24-h incubation, NAC concentration-dependently attenuated arsenite-induced depletion in glutathione (GSH) content and increases in the ratio of oxidized GSH/reduced GSH (GSSG/GSH ratio) in DRG explants. Furthermore, NAC inhibited arsenite-induced elevation in the expression of stress proteins, such as heat shock protein 70 and heme oxygenase 1, as well as arsenite-induced phosphorylation of p38 mitogen-activated protein kinase. Incubation with NAC ameliorated arsenite-induced apoptosis by abolishing both mitochondrial and endoplasmic reticulum (ER) pathways. In the mitochondrial pathway, NAC attenuated arsenite-induced elevation in Bcl-2 level and cytosolic cytochrome c, as well as arsenite-induced reduction in procaspase-3 levels. In the ER pathway, NAC suppressed arsenite-induced increases in activating transcription factor 6 and C/EBP homologous protein in the nuclear fraction. Furthermore, arsenite-induced reductions in procaspase-12 and elevation in BIP and caspase-12, an ER-specific enzyme, were prevented after NAC incubation. Taken together, our results demonstrate that NAC is neuroprotective against arsenite-induced oxidative injury in DRG explants. Furthermore, NAC inhibits arsenite-induced toxicity by inhibiting ER and mitochondrion activation. Our data indicate that NAC is potentially therapeutic for arsenite-induced peripheral neuropathy.
Assuntos
Acetilcisteína/farmacologia , Arsenitos/efeitos adversos , Sequestradores de Radicais Livres/farmacologia , Gânglios Espinais/efeitos dos fármacos , Gânglios Espinais/lesões , Estresse Oxidativo/efeitos dos fármacos , Fator 6 Ativador da Transcrição , Animais , Caspases/metabolismo , Relação Dose-Resposta a Droga , Gânglios Espinais/patologia , Glutationa , Proteínas de Choque Térmico HSP70 , Masculino , Técnicas de Cultura de Órgãos , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2 , Ratos , Ratos Sprague-DawleyRESUMO
The technique of in vivo voltametry and a paired recording paradigm were employed to study the age-related changes in N-methyl-d-aspartate (NMDA) function in regulating the striatal dopaminergic transmission in male Sprague-Dawley rats. Microinjection of NMDA (100pmol) consistently elicited larger striatal dopamine (DA) overflows from young rats (3-4 months old) than from aged rats (27-28 months old). Furthermore, the rate of clearance (T(c)) of the NMDA-evoked dopamine release was lower in the aged rats. Local application of dopamine evoked reversible electrochemical signals with similar amplitudes in both young and aged rats. However, T(c) was reduced and time course parameters were prolonged in the aged rats. While microejection of NMDA (1pmol) did not induce any dopamine overflow, simultaneous administration of NMDA and K(+) evoked larger dopamine releases than K(+) alone in the young striatum. Concomitant application of NMDA did not potentiate the K(+)-evoked dopamine release in the aged striatum. Taken together, with the reduced dopamine release in response to depolarizing stimuli, our in vivo electrochemical data suggest that age-related changes in NMDA function contribute to the impaired dopaminergic dynamics, including an attenuation of NMDA-evoked dopamine release and a diminished augmentation by K(+) of NMDA-induced dopamine release during the normal aging process.
Assuntos
Envelhecimento/metabolismo , Corpo Estriado/efeitos dos fármacos , Dopamina/metabolismo , N-Metilaspartato/farmacologia , Animais , Corpo Estriado/metabolismo , Eletroquímica , Masculino , Microinjeções , N-Metilaspartato/administração & dosagem , Potássio/farmacologia , Ratos , Ratos Sprague-DawleyRESUMO
Antioxidative mechanisms of vitamin D3 were evaluated both in vitro and in vivo. A 4-h incubation of brain homogenates at 37 degrees C increased the formation of Schiff base fluorescent products of malonaldehyde, an indicator of lipid peroxidation. Incubation with vitamin D3 dose-dependently suppressed auto-oxidation. The antioxidative potency for inhibiting zinc-induced lipid peroxidation was as follows: vitamin D3 > Trolox (a water-soluble analogue of vitamin E) > or = beta-estradiol > melatonin. In the presence of high dose of desferrioxamine, a metal chelator, vitamin D3 attenuated auto-oxidation. These in vitro data indicate that vitamin D3 may act as a terminator of the lipid peroxidation chain reaction. The antioxidative effect of vitamin D3 on zinc-induced oxidative injury was verified using local infusion of vitamin D3 in vivo. Intranigral infusion of zinc elevated lipid peroxidation in the infused substantia nigra and depleted striatal dopamine content at 7 days after infusion. Furthermore, elevated cytosolic cytochrome c and DNA ladder, indicatives of apoptosis, were demonstrated in the infused substantia nigra. Simultaneous infusion of vitamin D3 and zinc prevented oxidative injury and apoptosis induced by zinc alone. The involvement of glia-derived neurotrophic factor (GDNF) expression was excluded since vitamin D3 did not alter GDNF level in the infused substantia nigra at 24 h or 4 days after intranigral infusion of vitamin D3. Our results suggest that vitamin D3, independent of upregulation of GDNF expression, may acutely prevent zinc-induced oxidative injuries via antioxidative mechanisms.
Assuntos
Antioxidantes , Sistema Nervoso Central/metabolismo , Colecalciferol/farmacologia , Fármacos Neuroprotetores , Estresse Oxidativo/efeitos dos fármacos , Zinco/toxicidade , Animais , Apoptose/efeitos dos fármacos , Western Blotting , Colecalciferol/administração & dosagem , Cromatografia Líquida de Alta Pressão , Citocromos c/metabolismo , Citosol/metabolismo , Desferroxamina/farmacologia , Dopamina/metabolismo , Eletroquímica , Sequestradores de Radicais Livres/farmacologia , Fator Neurotrófico Derivado de Linhagem de Célula Glial/metabolismo , Imuno-Histoquímica , Injeções , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Ratos , Ratos Sprague-Dawley , Substância NegraRESUMO
Accumulation of transition metals has been suggested to be responsible for the deteriorated nigrostriatal dopaminergic system in Parkinson's patients. In the present study, the mechanism underlying the zinc-induced neurotoxicity was investigated in the nigrostriatal dopaminergic system in vivo. Our 6-methoxy-8-paratoluene sulfonamide quinoline fluorescence study showed zinc translocation in the infused nigral cells after intranigral infusion of zinc. Furthermore, lipid peroxidation in the zinc-infused substantia nigra was consistently elevated 4 h to 7 d after the infusion. At the same time, an abrupt increase in cytosolic cytochrome c content in the infused substantia nigra was observed 4 h after zinc infusion and gradually decreased to basal levels 7 d after infusion. Both TUNEL-positive neurons and DNA fragmentation, indicatives of apoptosis, were detected in the zinc-infused substantia nigra. Furthermore, striatal dopamine content was reduced 7 d after the infusion. In attempt to prevent zinc-induced neurotoxicity, vitamin D3 was systemically administered. Zinc-induced increases in lipid peroxidation and cytosolic cytochrome c in the infused substantia nigra were prevented by this treatment. Moreover, zinc-induced reduction in striatal dopamine content was attenuated after vitamin D3 treatment. Our in vivo data suggest that zinc-induced oxidative stress may result in apoptosis followed by reduced dopaminergic function in the nigrostriatal dopaminergic system. Furthermore, vitamin D3 prevented zinc-induced oxidative injuries in the rat brain.
Assuntos
Apoptose/efeitos dos fármacos , Colecalciferol/farmacologia , Fármacos Neuroprotetores/farmacologia , Substância Negra/efeitos dos fármacos , Substância Negra/patologia , Zinco/farmacologia , Animais , Cromatografia Líquida de Alta Pressão , Citocromos c/metabolismo , Dopamina/metabolismo , Marcação In Situ das Extremidades Cortadas , Peroxidação de Lipídeos , Masculino , Neurônios/citologia , Oxirredução , Estresse Oxidativo , Ratos , Ratos Sprague-Dawley , Substância Negra/metabolismoRESUMO
The effects of carboxyfullerene on a well-known neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite 1-methyl-4-phenyl-pyridinium (MPP+) were investigated. In chloral hydrate-anesthetized rats, cytosolic cytochrome c was elevated in the infused substantia nigra 4 h after an intranigral infusion of MPP+. Five days after local application of MPP+, lipid peroxidation (LP) was elevated in the infused substantia nigra. Furthermore, dopamine content and tyrosine hydroxylase (TH)-positive axons were reduced in the ipsilateral striatum. Concomitant intranigral infusion of carboxyfullerene abolished the elevation in cytochrome c and oxidative injuries induced by MPP+. In contrast, systemic application of carboxyfullerene did not prevent neurotoxicity induced by intraperitoneal injection of MPTP. In mice, systemic administration of MPTP induced a dose-dependent depletion in striatal dopamine content. Simultaneous injection of carboxyfullerene (10 mg/kg) actually potentiated MPTP-induced reduction in striatal dopamine content. Furthermore, systemic administration of carboxyfullerene (30 mg/kg) caused death in the MPTP-treated mice. An increase in the striatal MPP+ level and reduction in hepatic P450 level were observed in the carboxyfullerene co-treated mice. These data showed that systemic application of carboxyfullerene appears to potentiate MPTP-induced neurotoxicity while local carboxyfullerene has been suggested as a neuroprotective agent. Furthermore, an increase in striatal MPP+ level may contribute to the potentiation by carboxyfullerene of MPTP-induced neurotoxicity.
Assuntos
1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/farmacologia , Ácidos Carboxílicos/farmacologia , Dopaminérgicos/toxicidade , Compostos de Piridínio/toxicidade , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/administração & dosagem , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/antagonistas & inibidores , Animais , Apoptose/efeitos dos fármacos , Axônios/enzimologia , Axônios/metabolismo , Western Blotting , Sistema Enzimático do Citocromo P-450/metabolismo , Grupo dos Citocromos c/metabolismo , Citosol/efeitos dos fármacos , Citosol/metabolismo , Dopamina/metabolismo , Eletroquímica , Fulerenos , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/enzimologia , Masculino , Camundongos , Microinjeções , Neostriado/citologia , Neostriado/enzimologia , Neostriado/metabolismo , Estresse Oxidativo/fisiologia , Compostos de Piridínio/administração & dosagem , Compostos de Piridínio/antagonistas & inibidores , Ratos , Ratos Sprague-Dawley , Substância Negra/efeitos dos fármacos , Substância Negra/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismoRESUMO
One of the proposed pathologic actions underlying brain infarction is excess free radicals resulting from reoxygenation. In this paper we report an investigation of the neuroprotective effect of hypoxic preconditioning on transient focal ischemia-reperfusion injuries in rat brain. Female Wistar rats were subjected to 380 mmHg in an altitude chamber for 15 hours/day. Our ex vivo studies showed that auto-oxidation and iron-induced lipid peroxidation of brain homogenates of the four-week hypoxia-preconditioned rats were significantly lower than those of the normoxic rats. A focal infarction in the cerebral cortex of normoxic rats was consistently observed 24 hours after a 60-minute transient ischemic occlusion of the right middle cerebral artery and bilateral common carotid arteries. Hypoxic preconditioning in fact attenuated cortical infarction in a duration-dependent manner. Induction of the neuroprotection required two weeks of hypoxic preconditioning. Four weeks of hypoxic preconditioning significantly reduced the cortical infarcted area, the elevated lipid peroxidation, and resulted in an acute increase in cytosolic cytochrome c in the infarcted cortex of normoxic rats. The protective effect of four weeks of hypoxic preconditioning lasted seven days under a renormoxic condition. Our data suggest that oxidative stress may result in apoptosis in the transient focal ischemia-reperfusion injuries. Furthermore, hypoxic preconditioning attenuated cortical infarction in the rat brain. Although supplementation of antioxidants may encounter difficulty at the blood-brain barrier, hypoxic preconditioning is very likely to protect CNS targets from oxidative injuries without any barrier.
Assuntos
Infarto Encefálico/prevenção & controle , Encéfalo/metabolismo , Hipóxia , Traumatismo por Reperfusão/metabolismo , Animais , Encéfalo/citologia , Encéfalo/patologia , Infarto Encefálico/metabolismo , Infarto Encefálico/patologia , Grupo dos Citocromos c/metabolismo , Feminino , Hipóxia-Isquemia Encefálica , Peroxidação de Lipídeos , Oxirredução , Estresse Oxidativo , Distribuição Aleatória , Ratos , Ratos Wistar , Traumatismo por Reperfusão/patologiaRESUMO
AIM OF THE STUDY: S/B remedy prepared from Scutellaria baicalensis Georgi and Bupleurum scorzonerifolfium Willd, two herbals of Xiao-Tsai-Hu-Tang or Sho-Saiko-To (TJ-9), contains active flavonoids. In this study, the protective effect of S/B remedy on iron-induced neurodegeneration was investigated in the nigrostriatal dopaminergic system of rat brain. MATERIALS AND METHODS: The antioxidative activity of S/B remedy was studied using brain homogenates incubated with ferrous citrate (iron, 1M), S/B remedy, Trolox and melatonin. Furthermore, a Parkinsonian animal model by an intranigral infusion of iron in the anesthetized rats was employed to investigate the protective effect of S/B remedy in the nigrostriatal dopaminergic system. RESULTS: Our in vitro studies showed that S/B remedy was more potent than melatonin and equal to trolox in inhibiting iron-induced lipid peroxidation of brain homogenates. Our in vivo studies found that oral administration of S/B remedy dose-dependently attenuated iron-elevated lipid peroxidation in the infused substantia nigra (SN) and iron-depleted dopamine levels in the ipsilateral striatum. Furthermore, iron-induced reductions in glutathione (GSH) content and increases in GSSG (oxidized GSH)/GSH ratio in the infused SN were inhibited in S/B remedy-treated rats. Systemic S/B remedy attenuated the iron-induced increases in heme-oxygenase-1 levels and α-synuclein aggregation in the infused SN. Moreover, S/B remedy reduced iron-induced apoptosis via attenuating mitochondrial and endoplasmic reticulum stress. In addition, S/B remedy was anti-inflammatory as indicated by the attenuation of iron-induced elevations in inducible nitric oxide synthase and cyclo-oxygenase II levels as well as glial fibrillary acidic protein (a biological marker of astrocytes) and ED-1 (a protein indicative of activated microglia) levels in the infused SN of S/B remedy-treated rats. CONCLUSIONS: These findings suggest that oral administration of S/B remedy is protective against iron-induced neurodegeneration in the nigrostriatal dopaminergic system of rat brain. Therefore, S/B remedy may be therapeutically useful for the treatment of CNS neurodegenerative diseases.
Assuntos
Antioxidantes/farmacologia , Corpo Estriado/efeitos dos fármacos , Dopamina/metabolismo , Ferro/toxicidade , Fármacos Neuroprotetores/farmacologia , Extratos Vegetais/farmacologia , Scutellaria baicalensis/química , Substância Negra/efeitos dos fármacos , Animais , Apoptose/efeitos dos fármacos , Bupleurum , Cromatografia Líquida de Alta Pressão , Corpo Estriado/metabolismo , Eletroquímica , Peroxidação de Lipídeos , Masculino , Estresse Oxidativo , Ratos , Ratos Sprague-Dawley , Espectrometria de Fluorescência , Substância Negra/metabolismoRESUMO
The mechanism underlying sodium arsenite (arsenite)-induced neurotoxicity was investigated in rat brain. Arsenite was locally infused in the substantia nigra (SN) of anesthetized rat. Seven days after infusion, lipid peroxidation in the infused SN was elevated and dopamine level in the ipsilateral striatum was reduced in a concentration-dependent manner (0.3-5 nmol). Furthermore, local infusion of arsenite (5 nmol) decreased GSH content and increased expression of heat shock protein 70 and heme oxygenase-1 in the infused SN. Aggregation of alpha-synuclein, a putative pathological protein involved in several CNS neurodegenerative diseases, was elevated in the arsenite-infused SN. From the breakdown pattern of alpha-spectrin, both necrosis and apoptosis were involved in the arsenite-induced neurotoxicity. Pyknotic nuclei, cellular shrinkage and cytoplasmic disintegration, indicating necrosis, and TUNEL-positive cells and DNA ladder, indicating apoptosis was observed in the arsenite-infused SN. Arsenite-induced apoptosis was mediated via two different organelle pathways, mitochondria and endoplasmic reticulum (ER). For mitochondrial activation, cytosolic cytochrome c and caspase-3 levels were elevated in the arsenite-infused SN. In ER pathway, arsenite increased activating transcription factor-4, X-box binding protein 1, C/EBP homologues protein (CHOP) and cytosolic immunoglobulin binding protein levels. Moreover, arsenite reduced procaspase 12 levels, an ER-specific enzyme in the infused SN. Taken together, our study suggests that arsenite is capable of inducing oxidative injury in CNS. In addition to mitochondria, ER stress was involved in the arsenite-induced apoptosis. Arsenite-induced neurotoxicity clinically implies a pathophysiological role of arsenite in CNS neurodegeneration.
Assuntos
Arsenitos/toxicidade , Retículo Endoplasmático/efeitos dos fármacos , Síndromes Neurotóxicas/fisiopatologia , Estresse Oxidativo/efeitos dos fármacos , Compostos de Sódio/toxicidade , Animais , Apoptose/efeitos dos fármacos , Arsenitos/administração & dosagem , Caspase 3/efeitos dos fármacos , Caspase 3/metabolismo , Corpo Estriado/metabolismo , Citocromos c/efeitos dos fármacos , Citocromos c/metabolismo , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Retículo Endoplasmático/metabolismo , Glutationa/metabolismo , Proteínas de Choque Térmico HSP70/efeitos dos fármacos , Proteínas de Choque Térmico HSP70/metabolismo , Heme Oxigenase-1/efeitos dos fármacos , Heme Oxigenase-1/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Mitocôndrias/metabolismo , Necrose/patologia , Ratos , Ratos Sprague-Dawley , Compostos de Sódio/administração & dosagem , Substância Negra/metabolismo , alfa-Sinucleína/efeitos dos fármacos , alfa-Sinucleína/metabolismoRESUMO
In the present study, the protective effect of melatonin on sodium arsenite (arsenite)-induced apoptosis was investigated. Local infusion of arsenite elevated lipid peroxidation and depleted glutathione content in the infused substantia nigra (SN), as well as reduced striatal dopamine content. Systemic administration of melatonin diminished arsenite-induced oxidative injury. Furthermore, melatonin attenuated arsenite-induced increases in heat shock protein 70 and heme oxygenase-1 as well as phosphorylation of p38 mitogen-activated protein kinase and elevations in cyclooxygenase II and inducible nitric oxide synthase expression. Inhibition by melatonin of arsenite-induced apoptosis was determined by its attenuation of DNA fragmentation and terminal deoxytransferase-mediated dUTP-nick end labeling's positive cells in the infused SN of melatonin-treated rats. Melatonin reduced arsenite-induced apoptosis through mitochondrial and endoplasmic reticulum (ER) pathways. In the mitochondrial pathway, systemic melatonin inhibited arsenite-induced elevations in Bcl-2 and cytosolic cytochrome c as well as arsenite-induced reductions in procaspase-3 levels and elevations in active caspase-3 levels in the infused SN. Regarding the ER pathway, melatonin attenuated arsenite-induced elevations in activating transcription factor-4, CCAAT/enhancer binding protein (C/EBP) homologues protein, X-bon binding protein (XBP-1) and cytosolic immunoglobulin binding protein (BIP) as well as reductions in procaspase 12 levels. Moreover, aggregation of alpha-synuclein was reduced in the arsenite-infused SN of melatonin-treated rats. Our in vitro data showed that melatonin ameliorated arsenite-induced lipid peroxidation. Taken together, our data suggest that melatonin is neuroprotective against arsenite-induced oxidative injury in the nigrostriatal dopaminergic system of rat brain. Furthermore, the neuroprotective effects by melatonin on arsenite-induced apoptosis were mediated via inhibiting both mitochondrial and ER pathways. Accordingly, melatonin may be therapeutically useful for the treatment of arsenite-induced apoptosis in central nervous system.
Assuntos
Apoptose/efeitos dos fármacos , Arsenitos/farmacologia , Encéfalo/efeitos dos fármacos , Retículo Endoplasmático/efeitos dos fármacos , Melatonina/farmacologia , Mitocôndrias/efeitos dos fármacos , alfa-Sinucleína/metabolismo , Animais , Encéfalo/citologia , Encéfalo/metabolismo , Retículo Endoplasmático/metabolismo , Proteínas de Choque Térmico HSP70/metabolismo , Masculino , Mitocôndrias/metabolismo , Estresse Oxidativo , Ratos , Ratos Sprague-DawleyRESUMO
The neuroprotective effect of intermittent hypoxia on ferrous citrate (iron)-induced oxidative stress was investigated in the nigrostriatal dopaminergic system of rat brain. Female Wistar rats were subjected to 380 mm Hg in an altitude chamber for 15 h/day for 7, 14, or 28 days. Iron was locally infused in the substantia nigra of anesthetized rats. Seven days after infusion, lipid peroxidation was elevated in the infused substantia nigra and dopamine content and tyrosine hydroxylase-positive axons were decreased in the ipsilateral striatum in the normoxic rats. Intermittent hypoxic treatment prevented iron-induced oxidative injuries. Induction of the neuroprotection required 2 weeks. Intracerebroventricular infusion of L-buthionine-[S,R]-sulfoximine (L-BSO), which mimicked a reduced antioxidative condition, aggravated iron-induced oxidative injuries. Intermittent hypoxia ameliorated L-BSO-induced augmentation of iron-induced oxidative injuries. Basal GSH (glutathione) content, GSH/GSSG ratio, superoxide dismutase (SOD) and catalase activities in intact substantia nigra were not altered by intermittent hypoxia. Furthermore, intermittent hypoxia attenuated iron-induced reductions in GSH content, GSH/GSSG ratio, and SOD, iron-induced increase in catalase but had no effect on glutathione peroxidase. Our data suggest that intermittent hypoxia may protect the nigrostriatal dopaminergic system from iron-induced oxidative injuries. Moreover, antioxidative defensive systems may partially contribute to the neuroprotection by intermittent hypoxia.
Assuntos
Encéfalo/efeitos dos fármacos , Hipóxia/fisiopatologia , Ferro , Doença de Parkinson/fisiopatologia , Animais , Câmaras de Exposição Atmosférica , Encéfalo/metabolismo , Encéfalo/patologia , Butionina Sulfoximina/administração & dosagem , Catalase/metabolismo , Modelos Animais de Doenças , Vias de Administração de Medicamentos , Feminino , Glutationa/metabolismo , Dissulfeto de Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Ferro/administração & dosagem , Doença de Parkinson/patologia , Doença de Parkinson Secundária/induzido quimicamente , Ratos , Ratos Wistar , Substância Negra/efeitos dos fármacos , Substância Negra/metabolismo , Substância Negra/patologia , Superóxido Dismutase/metabolismoRESUMO
The mechanism that underlies the progressive degeneration of the dopaminergic neurons in Parkinson's disease (PD) is not clear. The Zn(2+) level in the substantia nigra of Parkinson's patients is increased. However, it is unknown whether Zn(2+) has a role in the degeneration of dopaminergic neurons. This study identifies an interaction between dopamine and Zn(2+) that induces cell death. When PC12 cells were pretreated with Zn(2+) before dopamine treatment, dopamine and Zn(2+) synergistically increased cell death, while Zn(2+) and H(2)O(2) had only additive effects on cell death. The synergistic effect appeared to be caused by increased apoptosis rather than necrosis. The synergistic effect was specific for Zn(2+). The synergistic effect was inhibited by thiol antioxidants but was not significantly affected by calcium channel blockers. There is a similar synergistic effect when dopamine and Zn(2+) were coinfused into the striatum, resulting in striatal dopamine content depletion in vivo. Thus, both dopamine oxidation and Zn(2+) are possibly linked to the degeneration of dopaminergic neurons.